The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid 25-35 I.c.v.-injected mice: Involvement of dopaminergic systems

Neuropsychopharmacology

Volumn 32, Issue 6, 2007, Pages 1261-1271

  Wang, Dayong ^a,b   Noda, Yukihiro ^a,c   Zhou, Yuan ^a,d   Mouri, Akihiro ^a   Mizoguchi, Hiroyuki ^a   Nitta, Atsumi ^a   Chen, Weiduo ^d   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Japanese Society of Pharmacopoeia   (Japan)

^c MEIJO UNIVERSITY   (Japan)

^d NORTHEAST AGRICULTURAL UNIVERSITY   (China)

Author keywords

Allosteric potentiating ligand; Alzheimer's disease; Beta amyloid25 35; Dopamine release; Galantamine; Nicotinic acetylcholine receptor

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMYLOID BETA PROTEIN[25-35]; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; GALANTAMINE; MECAMYLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE; SODIUM CHLORIDE; SULPIRIDE;

ALLOSTERISM; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; DISEASE MODEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEAR; HIPPOCAMPUS; IN VIVO STUDY; MALE; MENTAL TASK; MOUSE; NEUROMODULATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; RECOGNITION; TASK PERFORMANCE;

AMYLOID BETA-PROTEIN; ANIMALS; COGNITION DISORDERS; CONDITIONING (PSYCHOLOGY); CUES; DOPAMINE; EXTRACELLULAR SPACE; FEAR; GALANTAMINE; HIPPOCAMPUS; INJECTIONS, INTRAVENTRICULAR; MALE; MEMORY; MICE; MICE, INBRED ICR; MUSCARINIC ANTAGONISTS; PEPTIDE FRAGMENTS; RECEPTORS, NICOTINIC; RECOGNITION (PSYCHOLOGY); SCOPOLAMINE; SYNAPTIC TRANSMISSION;

EID: 34249090813     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301256     Document Type: Article

References (34)

1. Assal F, Cummings JL (2002). Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 15: 445-450.
2. Burghaus L, Schutz U (2000). Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res 76: 385-388.
3. Daumas S, Halley H, Lassalle JM (2004). Disruption of hippocampal CA3 network: effects on episodic-like memory processing in C57BL/6J mice. Eur J Neurosci 20: 597-600.
4. Eisele JL, Bertrand S, Galzi JL, Devillers-Thiery A, Changeux JP, Bertrand D (1993). Chimaeric nicotinic-serotoninergic receptor combines distinct ligand binding and channel specificities. Nature (Lond) 366: 479-483.
5. Enomoto T, Noda Y, Mouri A, Shin EJ, Wang D, Murai R et al (2005). Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D-aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68: 1765-1774.
6. Erkinjuntti T (2002). Treatment options: the latest evidence with galantamine (Reminyl). J Neurol Sci 203-204: 125-130.
7. Geerts H (2005). Indicators of neuroprotection with galantamine. Brain Res Bull 64: 519-524.
8. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice and rabbits. Brain Res 1033: 186-193.
9. Guan ZZ, Miao H, Tian JY, Unger C, Nordberg A, Zhang X (2001). Suppressed expression of nicotinic acetylcholine receptors by nanomolar beta-amyloid peptides in PC12 cells. J Neural Transm 10: 1417-1433.
10. Guan ZZ, Yu WF, Shan KR, Nordman T, Olsson J, Nordberg A (2003). Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation. J Neurosci Res 71: 397-406.
11. Hammond RS, Tull LE, Stackman RW (2004). On the delay-dependent involvement of the hippocampus in object recognition memory. Neurobiol Learn Mem 82: 26-34.
12. 24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav Brain Res 90: 133-145.
13. Hefco V, Yamada K, Hefco A, Hritcu L, Tiron A, Nabeshima T (2004). The interaction between the cholinergic and dopaminergic system in learning and memory process in rats. Rom J Physiol 41: 21-30.
14. Itoh A, Nitta A, Nadai M, Nishimura K, Hirose M, Hasegawa T et al (1996). Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein - infused rats. J Neurochem 66: 1113-1117.
15. Kamei H, Nagai T, Nakano H, Togan Y, Takayanagi M, Takahashi K et al (2006). Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK 1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 59: 75-84.
16. Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H et al (2005). Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 527: 77-85.
17. Levin ED, Simon BB (1998). Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 138: 217-230.
18. Lockhart BP, Benicourt C, Junien JL, Privat A (1994). Inhibitors of free radical formation fail to attenuate direct β-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J Neurosci Res 39: 494-505.
19. Maelicke A, Albuquerque EX (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 393: 165-170.
20. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX (2000). Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 113: 199-206.
21. Maurice T, Lockhart BP, Privat A (1996). Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706: 181-193.
22. Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A et al (2003). Cognitive impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J 17: 50-52.
23. Nordberg A (2001). Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol Psychiatry 49: 200-210.
24. Palmer AM (2002). Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci 23: 426-433.
25. Paxinos G, Franklin KBJ (2004). The Mouse Brain in Stereotaxic Coordinates, Compact, 2nd edn. Elsevier Academic Press: San Diego, USA.
26. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ (2000). Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci 3: 238-244.
27. Santos MD, Alkondon M, Aracava Y, Eisenberg HM, Maelicke A, Albuquerque EX (2002). The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61: 1222-1234.
28. Schroder H, Giacobini E, Struble RG, Zilles K, Maelicke A (1991). Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Neurobiol Aging 12: 259-262.
29. Sharp BM, Yatsula M, Fu Y (2004). Effects of galantamine, a nicotinic allosteric potentiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 309: 1116-1123.
30. Turner TJ (2004). Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J Neurosci 24: 11328-11336.
31. Van Dam D, De Deyn PP (2006). Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16: 59-69.
32. Wan Q, Luo ZP, Wang H (2003). Muscarinic receptor activities potentiated by desensitization of nicotinic receptors in rat superior cervical ganglia. Acta Pharmacol Sin 24: 657-662.
33. Woodruff-Pak DS, Santos IS (2000). Nicotinic modulation in an animal model of a form of associative learning impaired in Alzheimer's disease. Behav Brain Res 113: 11-19.
34. Woodruff-Pak DS, Vogel III RW, Wenk GL (2003). Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors. Neuroscience 117: 439-447.